Get this cocktail of risky medicine

Donald Trump was infected with the corona virus. Now the president of the United States is being treated with a combination of experimental drugs. What does this cocktail of active ingredients contain?

Currently, the news is causing a stir around the world: Donald trump is with the coronavirus SARS-CoV-2 infected. However, until now there has been confusion about his true health. However, the US President is known to have received various medications, the safety and efficacy of which have yet to be partially confirmed for Covid-19. Remedies include the drug remdesivir, the steroid dexamethasone, and a cocktail of antibodies.

According to his doctors, Trump, 74, also takes zinc, vitamin D, the stomach drug famotidine, the sleep hormone. Melatonin Y Aspirin one. At the top of the video, the doctors talk about Trump’s medication and also find the clip. here.

What is known so far about these agents and active ingredients?

Remdesivir: Controversial Ebola Drug Against Covid-19

Remdesivir is the only drug approved for the specific treatment of Covid-19, also subject to conditions in the EU since July. The United States already had limited use of the active ingredient as of early May. COVID-19-Patients approved in hospitals. US President Donald Trump described the move as “very promising” at the time.

Last Friday, Trump’s personal physician confirmed that the president of the United States was being treated with remdesivir. Many experts consider that the drug originally used to treat Ebola it was developed, but critically and not as a panacea for Covid-19 disease.

The spring studies had yielded different results: In China, there was no improvement in the health status of Covid 19 patients by administering remdesivir. An international study with more than 1,000 participants, on the other hand, showed that Remdesivir can shorten the recovery time in Covid 19 patients by an average of four days, from 15 to eleven days.

Kidney damage as a side effect?

According to the manufacturer, the American pharmaceutical company Gilead Sciences, the drug can also significantly reduce the risk of death in the event of a severe course of Covid-19. So far there is no scientific evidence for this.

This shows that the effects and possible side effects of the product have not been fully investigated.The EMA is currently examining whether Remdesivir is causing kidney complications.. There have been reports that some Covid-19 patients have suffered acute kidney damage after taking the drug.

The European Medicines Agency (EMA) recommends Remdesivir only for the treatment of adult patients with corona and adolescents from the age of twelve who have pneumonia and require oxygen. Therefore, the drug is not usually used in case of mild progressions. Officially, the president of the United States, Donald Trump, so far has only had mild symptoms.

Dexamethasone: recommended in seriously ill patients

Due to a temporary drop in oxygen, doctors also gave Trump the steroid dexamethasone. The World Health Organization (WHO) recommends the active ingredient in the treatment of seriously ill patients. However, it advises against treating patients with a mild course with active substances from the group of corticosteroids.

Antibody treatment: Therapy with residual risk

In addition to remdesivir, Trump also received a dose of an antibody cocktail, an experimental treatment method. According to his doctor, the President of the United States received the one-time therapy as a precautionary measure after he was diagnosed with corona infection.

The agent, which has not yet been approved, contains two antibodies against the SARS-CoV-2 coronavirus: according to a report in the journal “Science”, one of the two antibodies is extracted from a person who has recovered from Covid-19 . The second antibody originated in mice, whose immune systems in the laboratory resemble that of humans due to changes in the genome.

Human testing is still ongoing

What benefits and risks could arise from this mixture of antibodies has not yet been definitively established. A study on corona patients is still in progress. The pharmaceutical company Regeneron, which sells the agent, has released interim results of tests on people, which classify the risks as low. So far, however, these have only come from test subjects who were not treated in the hospital.

Also, as with any active ingredient that has not yet been approved, there is still a residual risk.